PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32211111-1 2020 This study aimed to determine the correlation of human epidermal growth factor receptor 2 (HER2) codon 655 A>G polymorphism with cardiotoxicity risk in HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D-T) adjuvant chemotherapy. Epirubicin 200-210 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-89 34694666-0 2021 Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation. Epirubicin 47-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-65 34312098-2 2022 The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). Epirubicin 175-185 erb-b2 receptor tyrosine kinase 2 Homo sapiens 285-319 34312098-2 2022 The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). Epirubicin 175-185 erb-b2 receptor tyrosine kinase 2 Homo sapiens 330-334 33299650-8 2020 The basal-like and HER2+ breast cancer primary cells showed chemosensitivities to paclitaxel and epirubicin with significant differences compared with luminal breast cancer primary cells (P < 0.05). Epirubicin 97-107 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-23 31776320-0 2020 Neoadjuvant chemotherapy of capecitabine + epirubicin + cyclophosphamide combination therapy ( "CEX" therapy) for HER-2 negative breast cancer, as retrospective study in our institute. Epirubicin 43-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-119 31776320-1 2020 BACKGROUND: We have modified and performed neoadjuvant chemotherapy (NAC) using capecitabine + epirubicin + cyclophosphamide combination therapy ( "CEX" ) for HER-2 negative breast cancer. Epirubicin 95-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 159-164 32461977-2 2020 This study is aimed at evaluating the efficacy of epirubicin/cyclophosphamide with weekly paclitaxel-trastuzumab as neoadjuvant chemotherapies in HER2+ BC patients. Epirubicin 50-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-150 32211111-1 2020 This study aimed to determine the correlation of human epidermal growth factor receptor 2 (HER2) codon 655 A>G polymorphism with cardiotoxicity risk in HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D-T) adjuvant chemotherapy. Epirubicin 200-210 erb-b2 receptor tyrosine kinase 2 Homo sapiens 91-95 31513391-6 2019 In vitro studies revealed that Tra-Ps-EPI with long-term storage stability could rapidly release drugs under a reductive condition and efficiently deliver a large amount of EPI HCl to HER2-positive SKOV-3 cells, leading to stronger cytotoxicity than the nontargeted Ps-EPI. Epirubicin 173-180 erb-b2 receptor tyrosine kinase 2 Homo sapiens 184-188 26359224-4 2015 For human epidermal growth factor receptors 2 (HER2) negative cancer, standard treatments are combinations of fluoropyrimidine and platinum with or without epirubicin or docetaxel in first-line therapy. Epirubicin 156-166 erb-b2 receptor tyrosine kinase 2 Homo sapiens 47-51 27693116-0 2017 Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. Epirubicin 0-10 erb-b2 receptor tyrosine kinase 2 Homo sapiens 187-191 31513391-0 2019 HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor. Epirubicin 74-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 31513391-3 2019 Here, we report on trastuzumab-decorated disulfide-cross-linked polymersomes (Tra-Ps) for specific delivery of epirubicin hydrochloride (EPI HCl) to HER2-positive SKOV-3 ovarian tumor. Epirubicin 111-135 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-153 31513391-3 2019 Here, we report on trastuzumab-decorated disulfide-cross-linked polymersomes (Tra-Ps) for specific delivery of epirubicin hydrochloride (EPI HCl) to HER2-positive SKOV-3 ovarian tumor. Epirubicin 137-144 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-153 27530622-0 2017 Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Epirubicin 88-98 erb-b2 receptor tyrosine kinase 2 Homo sapiens 14-18 27530622-8 2017 CONCLUSIONS: HER2 status is an independent prognostic biomarker in gastroesophageal adenocarcinomas receiving epirubicin-based chemotherapy. Epirubicin 110-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 13-17 27721408-5 2017 The glycolytic CAFs feed the extra pyruvate and lactate to tumor cells for augmentation of mitochondrial activity, and this energy metabolically coupled in a "host-parasite relationship" between catabolic CAFs and anabolic cancer cells confers the tumor cells with multiple drug resistance to several conventional clinical treatments including endocrine therapy (tamoxifen), Her-2-targeted therapy (herceptin) and chemotherapy (epirubicin). Epirubicin 428-438 erb-b2 receptor tyrosine kinase 2 Homo sapiens 375-380 24381054-8 2014 In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype. Epirubicin 60-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 52-56 25844392-2 2014 METHODOLOGY: Gemcitabine and epirubicin were covalently bond to anti-EGFR and anti-HER2/neu utilizing a rapid multi-phase synthetic organic chemistry reaction scheme. Epirubicin 29-39 erb-b2 receptor tyrosine kinase 2 Homo sapiens 83-87 25844392-9 2014 RESULTS: Dual-combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] produced greater levels of anti-neoplastic cytotoxicity than either of the covalent immunochemotherapeutics alone. Epirubicin 69-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 97-105 24381054-8 2014 In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype. Epirubicin 60-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 274-278 24381054-8 2014 In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype. Epirubicin 60-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 274-278 21920731-10 2012 In vitro response for Paclitaxel/Epirubicin was most frequently observed for cases in the basal category (40.3%) compared to HER2-like (25.8%) and luminal cases (28.6%). Epirubicin 33-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 125-129 23570501-2 2013 The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil (CMF) treatment. Epirubicin 215-225 erb-b2 receptor tyrosine kinase 2 Homo sapiens 153-157 23450278-0 2013 Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. Epirubicin 0-10 erb-b2 receptor tyrosine kinase 2 Homo sapiens 80-85 23450278-1 2013 BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer. Epirubicin 60-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 249-254 26225190-0 2012 Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate. Epirubicin 64-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 352-356 26225190-3 2012 Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes. Epirubicin 45-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-13 26225190-3 2012 Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes. Epirubicin 45-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-17 26225190-3 2012 Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes. Epirubicin 87-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-13 26225190-3 2012 Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes. Epirubicin 87-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-17 22240029-0 2012 HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Epirubicin 79-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 22191802-2 2012 A synthetic covalent bond between the UV-photoactivated epirubicin-(C(3)-amide) intermediate and the e-amine of lysine residues within the amino acid sequence of anti-HER2/neu monoclonal immunoglobulin was subsequently created by exposure to UV light (354 nm) for 15 minutes. Epirubicin 56-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 167-171 22191802-5 2012 Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin. Epirubicin 8-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 22191802-5 2012 Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin. Epirubicin 8-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 116-119 22191802-5 2012 Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin. Epirubicin 81-91 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 22191802-5 2012 Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin. Epirubicin 81-91 erb-b2 receptor tyrosine kinase 2 Homo sapiens 116-119 22191802-6 2012 Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival). Epirubicin 37-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-75 22191802-6 2012 Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival). Epirubicin 37-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-71 22191802-6 2012 Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival). Epirubicin 37-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 72-75 22191802-6 2012 Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival). Epirubicin 37-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-75 22191802-6 2012 Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival). Epirubicin 37-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-71 22191802-6 2012 Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival). Epirubicin 37-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 72-75 22191802-6 2012 Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival). Epirubicin 158-168 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-75 22191802-7 2012 Between final epirubicin-equivalent concentrations of 10(-8) and 10(-7) M there was a marked threshold increase in the mean cytotoxic anti-neoplastic activity for epirubicin-(C(3)-amide)-[anti-HER2/neu] from 9.9% to 66.9% (90.2% to 33.1% residual survival). Epirubicin 14-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 193-197 26229727-0 2011 Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium. Epirubicin 0-10 erb-b2 receptor tyrosine kinase 2 Homo sapiens 17-25 21788566-1 2011 PURPOSE: To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Epirubicin 44-54 erb-b2 receptor tyrosine kinase 2 Homo sapiens 163-197 26229727-1 2011 PURPOSE: Discover the anti-neoplastic efficacy of epirubicin-(C13-imino)-[anti-HER2/neu] against chemotherapeutic-resistant SKBr-3 mammary carcinoma and delineate the capacity of selenium to enhance it"s cytotoxic anti-neoplastic potency. Epirubicin 50-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 79-87 26229727-4 2011 The sulfhydryl-reactive epirubicin-(C13-imino)-EMCH intermediate was then combined with thiolated anti-HER2/neu monoclonal immunoglobulin. Epirubicin 24-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 103-107 26229727-6 2011 Anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] between the epirubicin-equivalent concentrations of 10-12 M and 10-7 M was determined by vitality staining analysis with and without the presence of selenium (5 muM). Epirubicin 27-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 56-60 26229727-7 2011 RESULTS: Epiribucin-(C13-imino)-[anti-HER2/neu] between epirubicin-equivalent concentrations of 10-8 M to 10-7 M consistently evoked higher anti-neoplastic potency than "free" non-conjugated epirubicin which corresponded with previous investigations utilizing epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-[anti-EGFR]. Epirubicin 56-66 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-42 26229727-7 2011 RESULTS: Epiribucin-(C13-imino)-[anti-HER2/neu] between epirubicin-equivalent concentrations of 10-8 M to 10-7 M consistently evoked higher anti-neoplastic potency than "free" non-conjugated epirubicin which corresponded with previous investigations utilizing epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-[anti-EGFR]. Epirubicin 191-201 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-42 26229727-7 2011 RESULTS: Epiribucin-(C13-imino)-[anti-HER2/neu] between epirubicin-equivalent concentrations of 10-8 M to 10-7 M consistently evoked higher anti-neoplastic potency than "free" non-conjugated epirubicin which corresponded with previous investigations utilizing epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-[anti-EGFR]. Epirubicin 191-201 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-42 26229727-8 2011 Selenium at 5 mM consistently enhanced the cytotoxic anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] at epirubicin equivalent concentrations (10-12 to 10-7 M). Epirubicin 80-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-113 26229727-8 2011 Selenium at 5 mM consistently enhanced the cytotoxic anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] at epirubicin equivalent concentrations (10-12 to 10-7 M). Epirubicin 80-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-117 19526361-0 2010 Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. Epirubicin 40-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 121-125 20332474-7 2010 This report suggests that combination therapy with epirubicin and cyclophosphamide followed by trastuzumab and paclitaxel was useful for HER2-positive IBC. Epirubicin 51-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 137-141 15738535-0 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Epirubicin 116-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 180-214 19480561-1 2009 Immunoconjugates of epirubicin were synthesized with monoclonal antibodies against the epidermal growth factor receptors, HER2/neu and EGFR, by creating a sulfhydryl-reactive epirubicin intermediate applying heterobifunctional succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), which was introduced at alpha-monoamide groups of the epirubicin carbohydrate moiety. Epirubicin 20-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-130 19480561-4 2009 Epirubicin-(anti-HER2/neu) and epirubicin-(anti-EGFR) had greater potency against chemotherapeutic-resistant SKBr-3 mammary carcinoma than did epirubicin at epirubicin-equivalent concentrations. Epirubicin 0-10 erb-b2 receptor tyrosine kinase 2 Homo sapiens 17-25 19480561-5 2009 Epirubicin-(anti-HER2/neu) was more potent than epirubicin-(anti-EGFR), and a synergistic level of antineoplastic activity was detected with an epirubicin immunoconjugate 50/50 combination. Epirubicin 144-154 erb-b2 receptor tyrosine kinase 2 Homo sapiens 17-25 18078328-4 2008 After treatment with SM, coexpression of HER2 and topoisomerase IIalpha (TOP2A) H661 and H69 cells is more sensitive to the TOP2 inhibitor, epirubicin. Epirubicin 140-150 erb-b2 receptor tyrosine kinase 2 Homo sapiens 41-71 18078328-8 2008 The data presented herein suggest that the expression of HER2 did not influence the SM-induced apoptosis of different types of lung cancer cells and that the SM up-regulation of HER2 and TOP2A expressions simultaneously augmented trastuzumab and epirubicin-induced deaths of lung cancer H661 and H69 cells. Epirubicin 246-256 erb-b2 receptor tyrosine kinase 2 Homo sapiens 178-182 18270380-0 2008 High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Epirubicin 145-155 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-42 18270380-9 2008 CONCLUSION: PST with weekly docetaxel and epirubicin were well-tolerated and very high pathological complete response rate was achieved in HER-2/neu-overexpression tumors. Epirubicin 42-52 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-148 17465239-6 2007 CONCLUSION: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel. Epirubicin 100-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 12-16 17465239-6 2007 CONCLUSION: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel. Epirubicin 100-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 17-20 16234514-1 2005 PURPOSE: The aim of the study was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients. Epirubicin 134-144 erb-b2 receptor tyrosine kinase 2 Homo sapiens 70-74 16234551-0 2005 Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer. Epirubicin 53-63 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-73 16137437-0 2005 HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. Epirubicin 134-144 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 15970926-9 2005 Our data suggest a potential role of HER-2 overexpression in predicting the efficacy of dose-dense epirubicin-containing chemotherapy and the need to confirm this hypothesis in future prospective studies. Epirubicin 99-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-42 17639997-7 2007 Therefore, the downregulation of the HER2 and TOP2A expression by SM with epirubicin may partially explain the SM and epirubicin cytotoxicity synergy effect in NSCLC. Epirubicin 74-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-41 17639997-7 2007 Therefore, the downregulation of the HER2 and TOP2A expression by SM with epirubicin may partially explain the SM and epirubicin cytotoxicity synergy effect in NSCLC. Epirubicin 118-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-41 17324279-0 2007 HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. Epirubicin 181-191 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-5 17324279-13 2007 Clinical response is inversely correlated with a risk of death in patients submitted to neoadjuvant chemotherapy and HER2 overexpression is the major prognostic factor in stage II and III breast cancer patients treated with a neoadjuvant docetaxel and epirubicin combination. Epirubicin 252-262 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-121 18086299-0 2007 CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Epirubicin 116-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 152-157 17200359-1 2007 PURPOSE: Findings from our previously published phase III randomized trial showed a high pathologic complete remission (CR) rate in patients with human epidermal growth factor receptor 2-positive breast cancer after the concurrent administration of trastuzumab and paclitaxel, followed by concurrent trastuzumab and 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) preoperative chemotherapy. Epirubicin 332-342 erb-b2 receptor tyrosine kinase 2 Homo sapiens 152-186 16781665-0 2006 Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Epirubicin 56-66 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-33 12852361-0 2003 [A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab]. Epirubicin 179-189 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-82 15292386-2 2004 In this retrospective subset analysis of patients with metastatic breast cancer enrolled in a randomized treatment trial, we investigated the response of patients with known HER-2/neu status to treatment with taxane-based epirubicin-paclitaxel (ET) chemotherapy compared with treatment with epirubicin-cyclophosphamide (EC) chemotherapy. Epirubicin 222-232 erb-b2 receptor tyrosine kinase 2 Homo sapiens 174-183 15093573-2 2004 HER2-positive patients received standard-dose trastuzumab plus epirubicin (60 or 90 mg/m(2))/cyclophosphamide (600 mg/m(2)) 3-weekly (EC60+H, n=26; EC90+H, n=25), for four to six cycles; 23 HER2-negative patients received EC alone (90/600 mg/m(2)) 3-weekly for six cycles (EC90). Epirubicin 63-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 14703068-0 2003 Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Epirubicin 38-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 84-88 14703068-0 2003 Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Epirubicin 38-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-92 14703068-2 2003 Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu. Epirubicin 36-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 230-238 11583189-0 2001 HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Epirubicin 149-159 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-32 11759828-2 2001 It was the purpose of this in vitro study to define the association between HER-2/neu overexpression and the sensitivity to the chemotherapeutic drug combinations of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and 5-fluorouracil, epirubicin and cyclophosphamide (FEC) of breast cancer cells derived from 140 chemotherapy-naive patients at the time of primary surgery. Epirubicin 242-252 erb-b2 receptor tyrosine kinase 2 Homo sapiens 82-85 11583189-11 2001 CONCLUSIONS: This study suggests that in node-positive breast cancer patients randomly treated with CMF or an epirubicin-based regimen, the predictive value of HER-2 may vary according to the Abs used in the immunohistochemistry assay. Epirubicin 110-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-165 15959941-5 2000 An ongoing German study is evaluating epirubicin/cyclophosphamide in combination with trastuzumab as first-line therapy of metastatic breast cancer in patients whose tumors overexpress HER2/neu protein. Epirubicin 38-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 185-193 9649144-14 1998 Among the prognostic biomarkers, overexpression of c-erbB2 oncogene and negative ER may have predictive value in epirubicin therapy in patients with advanced breast cancer. Epirubicin 113-123 erb-b2 receptor tyrosine kinase 2 Homo sapiens 51-58